ENvue Medical, Inc. Financial Summary

Quick Answer

ENvue Medical, Inc. reported Total Revenue of $2.56 million for fiscal year 2024.

ENvue Medical, Inc. — Key Financials by Year

Metric 2024 2023 2022 2021 2020 2019
Total Revenue $2.56M
+12.0%
$2.28M
+203.6%
$752.0K
-55.6%
$1.70M
+172.1%
$623.0K
+17.5%
$530.0K
+66.7%
Revenue (ASC 606) $2.56M
+12.0%
$2.28M
+203.6%
$752.0K
-55.6%
$1.70M
+172.1%
$623.0K
+17.5%
$530.0K
+66.7%
Net Income -$3.71M
+0.2%
-$3.71M
+31.9%
-$5.45M
+61.9%
-$14.28M
-230.1%
-$4.33M
+25.3%
-$5.79M
-39.5%
Diluted EPS -$13.73
+41.1%
-$23.32
-507.3%
-$3.84
Total Assets $3.63M
-45.6%
$6.67M
+13.5%
$5.88M
-31.8%
$8.62M
+4.8%
$8.23M
+304.2%
$2.04M
+28.9%
Cash and Equivalents $7.74M
+8.3%
$7.14M
+433.8%
$1.34M
+49.3%
Stockholders Equity $627.0K
-84.3%
$3.99M
+23.4%
$3.23M
-48.8%
$6.31M
+163.7%
$2.39M
+77.7%
$1.35M
+190.9%
R&D Expense $909.0K
+391.4%
$185.0K
-34.6%
$283.0K
-3.4%
$293.0K
+71.3%
$171.0K
-66.7%
$514.0K
-16.3%
Operating Income -$3.58M
-4.2%
-$3.44M
+31.4%
-$5.01M
+11.8%
-$5.68M
-20.4%
-$4.72M
+8.4%
-$5.15M
-19.7%
Gross Profit $1.51M
-1.9%
$1.54M
+820.4%
$167.0K
-78.3%
$770.0K
+259.8%
$214.0K
-23.8%
$281.0K
+75.6%
Shares Outstanding 378,941
+103.7%
186,028
-88.7%
1.64M
+17.2%
1.40M
-92.9%
19.85M
+372.2%
4.20M
+10.6%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $722.0K +92.0% +46.2%
Revenue (ASC 606) September 30, 2025 $722.0K +92.0% +46.2%
Net Income September 30, 2025 $510.0K +151.1% +112.8%
Diluted EPS September 30, 2025 -$0.91 +74.4% +11.7%
Total Assets September 30, 2025 $54.38M +1061.5% +5.6%
Cash and Equivalents September 30, 2025 $6.95M +432.6% +72.5%
Stockholders Equity September 30, 2025 $42.46M +2168.4% +4.9%
R&D Expense September 30, 2025 $221.0K -11.2% -77.3%
Operating Income September 30, 2025 -$2.25M -131.6% +43.5%
Gross Profit September 30, 2025 $189.0K +42.1% +640.0%
Shares Outstanding September 30, 2025 1.01M -63.7% +10110760.0%
  • ENvue Medical, Inc. reported Total Revenue of $2.56 million for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +12.0% in Total Revenue compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Revenue (ASC 606) of $2.56 million for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +12.0% in Revenue (ASC 606) compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Net Income of -$3.71 million for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +0.2% in Net Income compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Diluted EPS of $13.73 per share (loss) for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +41.1% in Diluted EPS compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Total Assets of $3.63 million for fiscal year 2024.
  • ENvue Medical, Inc. showed a decrease of -45.6% in Total Assets compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Cash and Equivalents of $7.74 million for fiscal year 2021.
  • ENvue Medical, Inc. showed an increase of +8.3% in Cash and Equivalents compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Stockholders Equity of $627.0 thousand for fiscal year 2024.
  • ENvue Medical, Inc. showed a decrease of -84.3% in Stockholders Equity compared to the prior fiscal year.
  • ENvue Medical, Inc. reported R&D Expense of $909.0 thousand for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +391.4% in R&D Expense compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Operating Income of -$3.58 million for fiscal year 2024.
  • ENvue Medical, Inc. showed a decrease of -4.2% in Operating Income compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Gross Profit of $1.51 million for fiscal year 2024.
  • ENvue Medical, Inc. showed a decrease of -1.9% in Gross Profit compared to the prior fiscal year.
  • ENvue Medical, Inc. reported Shares Outstanding of 378.9 thousand shares for fiscal year 2024.
  • ENvue Medical, Inc. showed an increase of +103.7% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment